

CONGENTO – Consortium for Genetically-Tractable Organisms

<https://neurodegenerationresearch.eu/survey/congento-consortium-for-genetically-tractable-organisms/>

Infrastructure name

CONGENTO - Consortium for Genetically-Tractable Organisms

Institute/location

Champalimaud Foundation, Lisbon, Portugal

Key contact

Rui M. Costa

Contact phone number

351 210480200

Contact email

ruicosta@fchampalimaud.org

Project/infrastructure description

The advent of model organisms where genetic manipulations became standard procedures revolutionized biomedical research. Among these organisms, fruitflies (*Drosophila melanogaster*), zebrafish (*Danio rerio*), and mice (*Mus musculus*) have been the most widely used. Studies using genetic manipulations in these species have led to fundamental findings in development, immunology, neuroscience, cancer, etc, that have been recognized with distinctions such as the Nobel Prize and the Lasker Award. They also have led to clinical trials and applications as vast as immunotherapy, chemotherapy, and drugs for psychiatric and cardiovascular disorders. CONGENTO - a Consortium for Genetically Tractable Organisms is the first worldwide infrastructure to integrate the expertise in fruitflies, zebrafish and mice in one research supporting facility. CONGENTO was born from the realization of the needs in Portugal and the opportunity of synergizing efforts by the participating institutions. Three main domains of services were identified as being critically needed in Portugal: 1) maintenance and hosting of genetically modified lines from the 3 species, either live or cryopreserved, 2) generation of new genetic lines and technologies in the different species, and 3) continuous education and certification in animal research and technology. CONGENTO has internationally recognized experts in these 3 domains, and has the combined spatial and equipment resources to support the Portuguese (and also European) Biomedical Research Community. CONGENTO is the first infrastructure in the world to synergize technology development across these 3 species, and provides state of the art services in all 3 organisms.

Date funding committed

01.01.2017

Date infrastructure operational

01.01.2016

Total capital cost (Euros)

€ 2,476,587

Does the 'Total Capital Cost' include other associated costs?

Yes

Current infrastructure status

Operational

Is this entry applicable to another section of this questionnaire?

Further information available at:

Not applicable

Types:

Capital Infrastructure

Member States:

Portugal

Diseases:

N/A

Years:

2016

Database Categories:

N/A

Database Tags:

N/A